Rosoxacin

Rosoxacin
Clinical data
Trade namesEradacil
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 1-Ethyl-4-oxo-7-pyridin-4-ylquinoline-3-carboxylic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.049.763
Edit this at Wikidata
Chemical and physical data
FormulaC17H14N2O3
Molar mass294.310 g·mol−1
3D model (JSmol)
Melting point290 °C (554 °F)
SMILES
  • CCn1cc(C(=O)O)c(=O)c2ccc(-c3ccncc3)cc21
InChI
  • InChI=1S/C17H14N2O3/c1-2-19-10-14(17(21)22)16(20)13-4-3-12(9-15(13)19)11-5-7-18-8-6-11/h3-10H,2H2,1H3,(H,21,22) checkY
  • Key:XBPZXDSZHPDXQU-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Rosoxacin (also known as acrosoxacin, tradename Eradacil) is a quinolone antibiotic indicated for the treatment of urinary tract infections and certain sexually transmitted diseases. Rosoxacin is not available in the United States.

It was developed in 1978 by George Lesher and his colleagues at Winthrop-Stearns (now part of sanofi-aventis), as an extension of the work that originally led to nalidixic acid.[1][2]

It is classified as a first generation quinolone.[3]

Synthesis

Rosoxacin synthesis:[4]

The synthesis of rosoxacin begins with a modified Hantzsch pyridine synthesis employing as component parts ammonium acetate, two equivalents of methyl propiolate, and one of 3-nitrobenzaldehyde. Oxidation of the resulting dihydropyridine (2) with nitric acid followed by saponification, decarboxylation, and reduction of the nitro group with iron and HCl acid gives aniline 3. This undergoes the classic sequence of Gould-Jacobs reaction with methoxymethylenemalonate ester to form the 4-hydroxyquinoline ring, and then alkylation with ethyl iodide and saponification of the ester to complete the synthesis of the antibacterial agent rosoxacin (4).

See also

References

  1. ↑ Carabateas, PM; Brundage, RP; Gelotte, KO; Gruett, MD; et al. (1984). "1-Ethyl-1,4-dihydro-4-oxo-7-(pyridinyl)-3-quinolinecarboxylic acids. I. Synthesis of 3- and 4-(3-aminophenyl)pyridine intermediates". Journal of Heterocyclic Chemistry. 21 (6): 1849–1856. doi:10.1002/jhet.5570210654.
  2. ↑ Carabateas, PM; Brundage, RP; Gelotte, KO; Gruett, MD; et al. (1984). "1-Ethyl-1,4-dihydro-4-oxo-7-(pyridinyl)-3-quinolinecarboxylic acids. II. Synthesis". Journal of Heterocyclic Chemistry. 21 (6): 1857–1863. doi:10.1002/jhet.5570210655.
  3. ↑ Przybilla B, Georgii A, Bergner T, Ring J (1990). "Demonstration of quinolone phototoxicity in vitro". Dermatologica. 181 (2): 98–103. doi:10.1159/000247894. PMID 2173670.
  4. ↑ Y.Lescher and P. M. Carabateas, U.S. Patent 3,907,808 (1975); Chem. Abstr., 84, 43880p (1975).


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.